Mar 29th, 2011
In this issue:
› Enrolment completed for Phase2 study of VivaGel® for treatment of BV
› Strengthening shareholderbase – new domestic and European investors
› Broad appeal of SPL’sdendrimer technology platform – agrochemicals and drug delivery
› Starpharma’s performance vs the market
Download: Shareholder Update: March 2011 ( pdf file, 530kb)
Mar 23rd, 2011
Starpharma today announced it had completed enrolment and all patient follow-up visits in its phase 2 study of VivaGel® for the treatment of bacterial vaginosis (BV).
This study investigated the effectiveness of VivaGel® administered once daily for seven days in the treatment of BV and enrolled 132 participants in the US. Data is now being processed and results will be available in the second quarter of this year.Read More
Mar 10th, 2011
Starpharma is today presenting at the ASX Emerging Growth conference in London.
More than 150 institutional fund managers are confirmed for the event. Starpharma is one of 18 companies participating in this invitation only event, and one of only two healthcare companies. Mesoblast is the other.
Presentation: SPL presents at ASX Emerging Growth Conference ( pdf file, 2MB)
Mar 3rd, 2011
Starpharma has been awarded $250,000 funding to enhance agrochemicals using its Priostar® dendrimers. The funding as part of the Victorian Government’s Small Technologies Industry Uptake Program (STIUP), will allow Starpharma to expand its Melbourne-based agricultural programs, further enhancing the commercial prospects of promising candidates.Read More
Feb 21st, 2011
Starpharma released its interim report and financial results for the half-year ended 31 December 2010.
- Cash position at 31 December 2010 $19.7M
- Net cash burn for the half-year $3.1M
- Operating cash outflows for the half-year $3.75M
- Reported loss $4.2M.
Jan 31st, 2011
The cash balance at 31 December 2010 was $19.7m compared to $22.8m at 30 June 2010. The Operating & Investing cash outflow of $1.5m for the quarter includes costs of the phase 2 bacterial vaginosis (BV) program. Progress with the Phase 2 BV acute-treatment study for VivaGel®, which commenced in July 2010 has been pleasing, with 90% of patients (119 from a total of 132) now enrolled.Read More
Jan 14th, 2011
Abstract: Starpharma is carving up and carving out in as many ways as possible product and application opportunities from its dendrimer chemistry platform. Dendrimers are synthetic, branch like chemical structures that can be engineered very precisely. The addition of smaller functional groups on the periphery or even with the greater structure is what makes the chemistry so versatile.
Download: Bioshares Issue 392 ( pdf file, 45kb)Read More
Dec 11th, 2010
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that details of the resolutions and the proxies received in respect of each resolution considered by the Starpharma Holdings Limited Annual General Meeting are set out in the attached proxy summary.
Nov 4th, 2010
Reckitt Benckiser has announced that it has completed its £2.5bn acquisition of SSL after gaining approval from more than 85% of SSL's shareholders by last Friday. As a result, SSL is now formally part of Reckitt Benckiser and its leading global condom brand Durex will be added to Reckitt’s portfolio of health and personal care “Powerbrands” which include Nurofen, Strepsils and Clearasil.Read More
Oct 20th, 2010
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.Read More